Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2830536 | 0.99 | DRD4 (0.40) | DRD4HTR1BDRD2DRD3HTR1D | |
| SCHEMBL2834214 | 0.90 | HTR7 (0.41) | DRD4DRD2DRD3NPC1RAB9A | |
| SCHEMBL13197320 | 0.90 | DRD4 (0.44) | DRD4DRD2DRD3NPC1MAPT | |
| SCHEMBL2836954 | 0.90 | DRD2 (0.44) | DRD4DRD2DRD3GBA1NPC1 | |
| Iodide SCHEMBL2832467 | 0.89 | DRD4 (0.43) | DRD4DRD2DRD3NPC1MAPT | |
| SCHEMBL2830994 | 0.88 | HTR1A (0.35) | DRD4DRD2DRD3GPR84MAPT | |
| SCHEMBL1384220 | 0.87 | F2 (0.39) | — | |
| SCHEMBL1383557 | 0.87 | DRD2 (0.47) | DRD4DRD2SMN1; SMN2ALDH1A1PIK3CD | |
| SCHEMBL1380229 | 0.87 | F2 (0.53) | DRD4DRD2DRD3MAPTRAB9A | |
| SCHEMBL1382661 | 0.87 | MTNR1A (0.43) | MAPTSMN1; SMN2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4796624-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | claimed |
| EP-1888538-B1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | claimed |
| EP-1888538-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | claimed |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. | 2006-11-09 | — | — | US | claimed |
| WO-2006117305-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | claimed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1888538-B1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1888538-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006117305-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HTR5A, NPY5R, HTR3A | DRD4 208/4885HTR1B 12/4885DRD2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.